The role of incretin-based therapies in prediabetes: A review

Primary Care Diabetes

Volumn 8, Issue 4, 2014, Pages 286-294

  Ahmadieh, Hala ^a   Azar, Sami T ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

DPP IV inhibitor; GLP 1 agonist; Incretin based therapy; Oral diabetic medications; Prediabetes; Type 2 diabetes mellitus

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INCRETIN; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; GLUCAGON LIKE PEPTIDE 1; GLUCOSE BLOOD LEVEL;

B LYMPHOCYTE; DIASTOLIC BLOOD PRESSURE; GLYCEMIC CONTROL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; PATHOPHYSIOLOGY; REVIEW; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; WEIGHT REDUCTION; AGONISTS; ANIMAL; BLOOD; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; METABOLISM; PREDIABETIC STATE; TREATMENT OUTCOME;

ANIMALS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; PREDIABETIC STATE; TREATMENT OUTCOME;

EID: 84916641113     PISSN: 17519918     EISSN: 18780210     Source Type: Journal    
DOI: 10.1016/j.pcd.2014.02.005     Document Type: Review

References (84)

1. American Diabetes Association Standards of medical care in diabetes-2013 Diabetes Care 35 1 2013 S11 S63
2. The International Expert Committee International expert committee report on the role of the A1c assay in the diagnosis of diabetes Diabetes Care 32 7 2009 1327 1334
3. WHO Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus Diabetes Res. Clin. Pract. 93 3 2011 299 309
4. Report of a WHO/IDF Consultation: Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia 2006 WHO Geneva http://whqlibdoc.who.int/publications/2006/924159 4934-eng.pdf
5. IDF DIABETES ATLAS Sixth edition. Online version of IDF Diabetes Atlas: www.idf.org/diabetesatlas. ISBN: 2-930229-85-3.
6. A.G. Tábak, C. Herder, and W. Rathmann Prediabetes: a high-risk state for diabetes development Lancet 12 2012 60283 60289 10.1016/S0140-6736
7. S.E. Kahn, M.E. Cooper, S. Del, and Prato Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future Lancet 13 2013 62154 62156 10.1016/S0140-6736
8. R.A. DeFronzo Current issues in the treatment of type 2 diabetes. Overview of newer agents: where treatment is going Am J Med 123 Suppl. 2010 S38 S48
9. B.L. Wajchenberg Beta-cell failure in diabetes and preservation by clinical treatment Endocr. Rev. 28 2007 187 218
10. G. Weir, and S. Bonner-Weir Five stages of evolving b-cell dysfunction during progression to diabetes Diabetes 53 12, suppl 3 2004 S16 S21
11. M.A.M.A. Abdul-Ghani, and T.D. DeFronzo Contributions of B-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose Diabetes Care 29 2006 1130 1139
12. D.M. Nathan, M.B. Davidson, R.A. Defronzo, R.J. Heine, R.R. Henry, R. Pratley, and B. Zinman Impaired fasting glucose and impaired glucose tolerance Diabetes Care 30 2007 753 759
13. T.A. Buchanan, A.H. Xiang, R.K. Peters, S.L. Kjos, A. Marroguin, J. Goico, C. Ochoa, S. Tan, K. Berkowitz, H.N. Hodis, and S.P. Azzen Preservation of pancreatic-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women Diabetes 51 2002 2796 2803
14. X.R. Pan, G.W. Li, Y.H. Hu, J.X. Wang, W.Y. Yang, Z.X. AN, Z.X. Hu, J. Lin, J.Z. Xiao, H.B. Cao, P.A. Liu, X.G. Jiang, Y.Y. Jiang, J.P. Wang, H. Zheng, P.H. Bennett, and B.V. Howard Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study Diabetes Care 20 1997 537 544
15. E. Rask, T. Olsson, S. Soderberg, J.J. Holst, A. Tura, and G. Pacini Insulin secretion and incretin hormones after oral glucose in non-obese subjects with impaired glucose tolerance Metabolism 53 5 2004 624 631
16. M. Laakso, J. Zilinskaite, T. Hansen, T.W. Boesgaard, M. Vanttinen, and A.A. Stancakova Insulin sensitivity, insulin release and glucagon-like peptide-1 levels in persons with impaired fasting glucose and/or impaired glucose tolerance in the EUGENE2 study Diabetologia 51 3 2008 502 511
17. A. Fritsche, N. Stefan, E. Hardt, H. Haring, and M. Stumvoll Characterisation of beta-cell dysfunction of impaired glucose tolerance: evidence for impairment of incretin-induced insulin secretion Diabetologia 43 7 2000 852 858
18. G. Bock, C. Dalla Man, M. Campioni, E. Chittilapilly, R. Basu, and G.G. Toffolo Pathogenesis of prediabetes: mechanisms of fasting and postprandial hyperglycemia in people with impaired fasting glucose and/or impaired glucose tolerance Diabetes 55 12 2006 3536 3549
19. R. Abu-Hamdah, A. Rabiee, and G.S. Meneilly Clinical review: the extrapancreatic effects of glucagon-like peptide-1 and related peptides J. Clin. Endocrinol. Metab. 94 2009 1843 1852
20. A. Vella Mechanism of action of DPP-4 inhibitors-new insights J. Clin. Endocrinol. Metab. 97 8 2012 2626 2628
21. J. Holst On the physiology of GIP and GLP-1 Horm. Metab. Res. 36 2004 747 754
22. L.L. Baggio, and D.J. Drucker Biology of incretins: GLP-1 and GIP Gastroenterology 132 2007 2131 2157
23. J.B. Buse, D.C. Klonoff, L.L. Nielsen, X. Guan, C.L. Bowlus, J.H. Holcombe, and D.G. Maggs M. E. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials Clin. Ther. 29 2007 139 153
24. T. Vilsbøll, B. Brock, H. Perrild, K. Levin, H.H. Lervang, K. Kolendorf, T. Krarup, O. Schmitz, M. Zdravkovic, T. Le-Thi, and S. Madsbad Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with type 2 diabetes mellitus Diabet. Med. 25 2008 152 156
25. K. Ban, M.H. Noyan-Ashraf, J. Hoefer, S.S. Bolz, D.J. Drucker, and M.M. Husain Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways Circulation 117 2008 2340 2350
26. A. Nauck, A. Michael, T. Vilsbøll, B. Gallwitz, A. Garber, and S. Madsbad Incretin-based therapies Diabetes Care 32 Suppl 2 2009 S223 S231
27. J. Fontana, Z. Červinková, and M. Anděl Effects of GLP-1 (glucagon-like peptide 1) on liver Vnitr Lek. 59 7 2013 551 558
28. G. Svegliati-Baroni, S. Saccomanno, C. Rychlicki, L. Agostinelli, S. De Minicis, C. Candelaresi, G. Faraci, D. Pacetti, M. Vivarelli, D. Nicolini, P. Garelli, A. Casini, M. Manco, G. Mingrone, A. Risaliti, G.N. Frega, A. Benedetti, and A. Gastaldelli Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis Liver Int. 31 9 2011 1285 1297
29. C.F. Deacon, and N. Marx Potential cardiovascular effects of incretin-based therapies Expert Rev. Cardiovascular Therapy 10 3 2003 337 351
30. P. Anagnostis, V.G. Athyros, F. Adamidou, A. Panagiotou, M. Kita, A. Karagiannis, and D.P. Mikhailidis Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control Diab. Obes. Metab. 13 2011 302 312
31. K. Ban, M.H. Noyan-Ashraf, J. Hoefer, S.S. Bolz, D.J. Drucker, and M. Husain Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways Circulation 117 2008 2340 2350
32. T. Nyström, M.K. Gutniak, Q. Zhang, F. Zhang, J.J. Holst, B. Ahrén, and A. Sjöholm Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease Am. J. Physiol. Endocrinol. Metab. 287 6 2004 E1209 E1215
33. J. Petrie The cardiovascular safety of incretin-based therapies: a review of the evidence Cardiovasc. Diabetol. 12 2013 130
34. R. Bergenstal, G. Daniels, J. Mann, S. Nissen, S. Pocock, and B. Zinman Liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADERTM) trial: rationale and study design Diabetes 60 Suppl. 1 2011 A612 A613
35. Merck & Co. TECOS: A randomized, placebo controlled clinical trial to evaluate cardiovascular outcomes after treatment with sitagliptin in patients with type 2 diabetes mellitus and inadequate glycemic control (ClinicalTrials.gov identifier: NCT00790205). 2008. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00790205?term=TECOS&rank=1.
36. AstraZeneca. Does saxagliptin reduce the risk of cardiovascular events when used alone or added to other diabetes medications (SAVOR-TIMI 53). 2010. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01107886?term=saxagliptin?cardiovascular&rank=1. Accessed 9 May 2012.
37. Amylin Pharmaceuticals, Inc. Exenatide study of cardiovascular event lowering trial (EXSCEL): a trial to evaluate cardiovascular outcomes after treatment with exenatide once weekly in patients with type 2 diabetes mellitus. 2010. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01144338?term=EXSCEL&rank=1.
38. Boehringer Ingelheim Pharmaceuticals. A multicentre, international, randomised, parallel group, double blind study to evaluate cardiovascular safety of linagliptin versus glimepiride in patients with type 2 diabetes mellitus at high cardiovascular risk (CAROLINA). 2010. Available from: http://clinicaltrials.gov/ct2/show/NCT01243424?term=CAROLINA?linagliptin&rank=1.
39. T. Vilsbøll, M. Christensen, A.E. Junker, F.K. Knop, and L.L. Gluud Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials BMJ 344 2012 doi: http://dx.doi.org/10.1136/bmj.d7771
40. J.B. Buse, J. Rosenstock, and G.G. Sesti Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) Lancet 374 2009 39 47
41. J.B. Buse, G. Sesti, and W.E. W.E. Schmidt Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents Diabetes Care 33 2010 1300 1303
42. D.J. Drucker, J.B. Buse, and K. Taylor Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study Lancet 372 2008 1240 1250
43. I. Hadjiyanni Exendin-4 modulates diabetes onset in nonobese diabetic mice Endocrinology 149 2008 1338 1349
44. X.R. Pan, G.W. Li, and Y.H. Hu Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerances. The Da Qing IGT and Diabetes Study Diabetes Care 20 4 1997 537 544
45. N.A. Sherry Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells Endocrinology 148 2007 5136 5144
46. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin N Engl J Med 346 2002 393 403
47. C.A. Sheffield Off-label use of exenatide for the management of insulinresistant type 1 diabetes mellitus in an obese patient with human immunodeficiency virus infection Pharmacotherapy 27 2007 1449 1455
48. J. Lindstrom, J.G. Eriksson, and T.T. Valle Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial J. Am. Soc. Nephrol. 14 7 Suppl 2 2003 S108 S113
49. A.N. Paisley Stabilizing effect of exenatide in a patient with C-peptidenegative diabetes mellitus Diabet. Med. 26 2009 935 938
50. T.A. Buchanan, A.H. Xiang, and R.K. Peters Preservation of pancreatic-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high risk Hispanic women Diabetes 51 9 2002 2796 2803
51. W.O. Creutzfeldt Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I (7-36) amide in type 1 diabetic patients Diabetes Care 19 1996 580 586
52. H.C. Gerstein, S. Yusuf, and J. Bosch Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial Lancet 368 9541 2006 1096 1105
53. W.L. Suarez-Pinzon Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor restores normoglycaemia in non-obese diabetic mice Diabetologia 52 2009 1680 1682
54. J. Bosch, S. Yusuf, and H.C. Gerstein Effect of ramipril on the incidence of diabetes N. Engl. J. Med. 355 15 2006 1551 1562
55. L. Tian Reversal of new-onset diabetes through modulating inflammation and stimulating beta-cell replication in nonobese diabetic mice by a dipeptidyl peptidase IV inhibitor Endocrinology 151 2010 3049 3060
56. J.L. Chiasson, R.G. Josse, and R. Gomis Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance. The STOP-NIDDM trial JAMA 290 4 2003 486 494
57. C.Y. Pan, U. Gao, and J.W. Chen Efficacy of acarbose in Chinese subjects with impaired glucose tolerance Diabetes Res. Clin. Pract. 61 3 2003 183 190
58. J.S. Torgerson, J. Hauptman, M.N. Boldrin, and L. Sjöström Xenical in the prevention of Diabetes in Obese Subjects (XENDOS) study Diabetes Care 27 2004 155 161
59. J.J. McMurray, R.R. Holman, and S.M. Haffner Effect of valsartan on the incidence of diabetes and cardiovascular events N. Engl. J. Med. 362 16 2010 1477 1490
60. R.R. Holman, S.M. Haffner, and J.J. McMurray Effect of nateglinide on the incidence of diabetes and cardiovascular events N. Engl. J. Med. 362 16 2010 1463 1476
61. A.J. Scheen NAVIGATOR: a trial of prevention of cardiovascular complications and type 2 diabetes with valsartan and/or nateglinide Rev. Med. Liege. 65 4 2010 217 223
62. M.S. Kirman, R.R. Shankar, S. Shankar, C. Shen, E. Brizendine, A. Baron, and J. Mcgill Treating postprandial hyperglycemia does not appear to delay progression of early type 2 diabetes Diabetes Care 29 9 2006 2095 2101
63. B. Sudre, P. Broqua, and R.B. White Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male zucker diabetic fatty rats Diabetes 51 2002 1461 1469
64. Y. Moritoh, K. Takeuchi, and M. Hazama Combination treatment with alogliptin and voglibose increases active GLP-1 circulation, prevents the development of diabetes and preserves pancreatic beta-cells in prediabetic db/db mice Diabetes Obes. Metab. 12 2010 224 233
65. K.M. Utzschneider, J. Tong, and B. Montgomery The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose Diabetes Care 31 2008 108 113
66. J. Rosenstock, J. Foley, and M. Rendell Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance Diabetes Care 31 2008 30 35
67. G. Bock, C. Dalla Man, and F. Micheletto The effect of DPP-4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose Clin. Endocrinol. (Oxf.) 73 2010 189 196
68. L. Perreault, C.D. Man, and D.M. Hunerdosse Incretin action maintains insulin secretion, but not hepatic insulin action, in people with impaired fasting glucose Diabetes Res. Clin. Pract. 90 2010 87 94
69. A. Astrup, S. Rossner, G.L. Van, and A. Rissanen Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study Lancet 374 2009 1606 1616
70. R. DeFronzo, and M. Abdul-Ghani Preservation of b-cell function: the key to diabetes prevention J. Clin. Endocrinol. Metab. 96 8 2011 2354 2366
71. J. Rosenstock, L.J. Klaff, and S. Schwartz Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without prediabetes Diabetes Care. 33 2010 1173 1175
72. Byetta [Package Insert] 2007 Amylin Pharmaceuticals, Inc. San Diego, CA
73. A. Crespel, B.F. De, and L.L. Gros Effects of glucagon and glucagon-like peptide-1- (7-36) amide on C cells from rat thyroid and medullary thyroid carcinoma CA-77 cell line Endocrinology 137 1996 3674 3680
74. y. Lamari, C. Boissard, and M.S. Moukhtar Expression of glucagon-like peptide 1 receptor in a murine C cell line: regulation of calcitonin gene by glucagon-like peptide 1 FEBS Lett. 393 1996 248 252
75. M. Parks, and C. Rosebraugh Weighing risks and benefits of liraglutide - the FDA's review of a new antidiabetic therapy N. Engl. J. Med. 362 2010 774 777
76. U.S. Food Drug Administration, Center for Drug Evaluation and Research. Exenatide (marketed as BYETTA): acute pancreatitis 2008 FDA Drug Safety Newsletter Silver Spring, MD: US Department of Health and Human Services 1 http://www.fda.gov/Drugs/DrugSafety/DrugSafetyNews letter/ucm109165.htm [4 May 2011]
77. Food and Drug Administration. Information for healthcare professionals: exenatide (marketed as BYETTA) - 8/2008 update. 2008; http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformation forPatientsandProviders/ucm124713.htm [4 May 2011].
78. D.D. Dore, J.D. Seeger, and C.K.C.K. Arnold Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide Curr. Med. Res. Opin. 25 2009 1019 1027
79. S.S. Engel, D.E. Williams-Herman, and G.T. Golm Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis Int. J. Clin. Pract. 64 2010 984 990
80. D.M. Nathan, J.B. Buse, and M.B. Davidson Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 32 2009 193 203
81. J.B. Buse, R.R. Henry, and J. Han Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylureatreated patients with type 2 diabetes Diabetes Care 27 2004 2628 2635
82. R.A. DeFronzo, R.E. Ratner, and J. Han Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes Diabetes Care 28 2005 1092 1100
83. M. Nauck, A. Fri, and K. Hermansen K. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (Liraglutide Effect and Action in Diabetes)-2 study Diabetes Care 32 2009 84 90
84. V.R. Aroda The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review Diabetes Metab. Res. Rev. 27 2011 528 542